Graft rejection is a serious problem associated with tissue or organ
transplantation (e.g., allotransplantation or xenotransplantation),
performed to treat various organ failures (e.g., liver, heart, lung,
kidney, or pancreas). Described are pharmaceutical compositions for
suppressing, treating, or preventing graft rejection comprising a
substance having an activity to modulate signal transduction mediated by
AILIM, and a pharmaceutically acceptable carrier.
